Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli said,

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.

Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 billion deal will not raise competitive concerns.

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers:

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by Catalent, saying she is concerned it could have antitrust implications.

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk , from acquiring contract drug manufacturer Catalent ,